BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 28, 2024
See today's BioWorld
Home
» New Acceleron, Celgene Deal Anything But 'Anemic'
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
New Acceleron, Celgene Deal Anything But 'Anemic'
Aug. 4, 2011
By
Catherine Shaffer
No Comments
Celgene Corp. will pay $25 million up front to Acceleron Pharma Inc. plus up to $217 million more in potential milestones, under a new collaboration agreement between the two companies for the development of an anemia therapeutic.
BioWorld